• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Replimune Group (REPL) Is Up 23.1% And What's Next

    Simply Wall St·10/29/2026 06:54:13
    Listen to the news
    • Replimune Group reported second quarter 2026 results with a net loss of US$57.12 million and basic loss per share of US$0.54, both lower than a year earlier.
    • The six month figures also showed a smaller net loss and loss per share than the prior year, which highlights tighter cost control and operating discipline as Replimune Group prepares to scale its commercial rollout.
    • We will now look at how Replimune Group's narrower quarterly loss shapes the investment narrative around TUDRIQEV and potential commercialization plans.

    Compare Replimune Group's tightening losses with other healthcare names preparing for potential inflection points by scanning our hand picked 36 healthcare AI stocks.

    Replimune Group Investment Narrative Recap

    To own Replimune Group, you need to believe TUDRIQEV can move from a single accelerated approval into a durable commercial franchise while the broader RPx pipeline adds depth. The smaller quarterly and six month losses show tighter spending as that shift begins, but the short term story still revolves around how quickly treatment centers start using TUDRIQEV.

    The biggest near term catalyst remains early prescription trends once the in house launch reaches those first 200 hospital accounts. The main risk is that uptake, reimbursement, or the IGNYTE-3 confirmatory trial progress more slowly than hoped. The latest results do not fundamentally change either side of that equation.

    The earnings report for the quarter and six months to September 30, 2026 is the key update here. Replimune Group reported a net loss of US$57.12 million for the quarter and US$126.89 million for the half year, both smaller than a year earlier, with basic and diluted loss per share at US$0.54 for the quarter and US$1.26 for the half.

    For you as a shareholder, that matters because it speaks to how long the business can fund the TUDRIQEV launch and IGNYTE-3 without putting even more pressure on the balance sheet. Execution risk around commercialization and confirmatory data is unchanged, but a slower cash burn gives management a little more room to focus on those operational milestones.

    Replimune Group's narrative projects US$296.9 million revenue and US$47.4 million earnings by 2029. This implies yearly top line growth from effectively zero and an earnings swing of about US$344 million from current earnings of a US$297 million loss to the forecast consensus earnings.

    Uncover why Replimune Group's fair value indicates a 21% potential upside to its current price, a discount that may not last much longer.

    NasdaqGS:REPL 1-Year Stock Price Chart
    NasdaqGS:REPL 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts frame payer coverage as the real swing factor for Replimune Group. Before this earnings release, the bullish camp was working off forecasts of about US$458.6 million in revenue and US$84.4 million in earnings by 2029. As a result, your view on reimbursement strength and cash collection could shift again as the latest loss figures settle into those models.

    Explore 3 other Replimune Group fair value estimates, including one that suggests as much as 574% upside from the current price!

    Form Your Own Verdict

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Replimune Group?

    Once you have a view on Replimune Group, it can help to stress test that thinking against a wider watchlist. The Simply Wall St screener makes it easy to line up different types of opportunities by balance sheet strength, income focus, or return potential and see how they compare on the same set of fundamentals.

    • If capital preservation sits high on your list, start with a 32 resilient stocks with low risk scores that prioritise resilience over drama in your portfolio.
    • For investors hunting for long term compounding opportunities, broaden your radar with a 19 high quality undiscovered gems that pair quality fundamentals with relatively low market attention.
    • If dependable income matters most to you, focus your research on a 6 dividend fortresses aimed at stocks offering substantial yields backed by solid fundamentals.